arrow
S

S. Supiot

centre rene gauducheau
H指数:40
被引数:7,287

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial

高危前列腺癌患者长期雄激素剥夺治疗后行高剂量放疗(GETUG AFU 18):一项随机、III期临床试验

2026-08-240
PRE
Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis

不良病理特征对术后放疗联合激素治疗在复发性前列腺癌中潜在获益的影响:一项个体患者数据Meta分析

2026-07-280
PRE
OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial

OLIGOPELVIS 2-GETUG P12试验:前列腺癌寡复发盆腔/腹主动脉旁淋巴结的择区淋巴结放疗的早期毒性——一项随机III期试验

2026-05-150
PRE
Dose-dependent cerebrovascular impact of pediatric brain radiotherapy revealed by advanced MRI: the AVARTHEC study

通过高级MRI揭示儿科脑放疗的剂量依赖性脑血管影响:AVARTHEC研究

2026-05-090
OAAI
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)
2025-11-010
PRE
Reirradiation of lung, breast and bone tumours, suggestions from the Recommendations Commission of the Société francaise de radiothérapie oncologique

肺,乳腺和骨肿瘤的再照射,法国放射肿瘤学协会建议委员会的建议

2025-11-010
PRE
Radiotherapy for penile cancers: 2025 update

阴茎癌的放射治疗:2025年更新

2025-11-010
OAAI
Reply to Federico Iori, Emanuele Alì, and Cinzia Iotti’s Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.019

回复Federico Iori、Emanuele Alì和Cinzia Iotti的致编辑信:关于Nicolas Demogeot、Paul Sargos、Julia Salleron等人关于局部中高危前列腺癌短期雄激素剥夺疗法与高剂量放疗的研究:GETUG 14随机III期试验结果。欧洲泌尿学杂志。待发表。https://doi.org/10.1016/j.eururo.2025.07.019

2025-10-230
PRE
Reply to Mattia Longoni, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.019

回复Mattia Longoni、Giorgio Gandaglia和Francesco Montorsi致编辑的信:关于Nicolas Demogeot、Paul Sargos、Julia Salleron等人关于局部中高风险前列腺癌短期雄激素剥夺疗法联合高剂量放疗的研究结果——GETUG 14随机III期试验的结果。欧洲泌尿学杂志。待发表。https://doi.org/10.1016/j.eururo.2025.07.019

2025-10-230
PRE
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial

调整阿比特龙-泼尼松交叉对原发转移性去势敏感前列腺癌的影响:PEACE-1试验的事后分析

2025-09-270
PRE
Urinary organs-at-risk for radiotherapy following radical prostatectomy: contouring guidelines on behalf of the Francophone Group of Urological Radiation Therapy (GFRU)

根治性前列腺切除术后放射治疗的泌尿器官危险区勾画指南:法国泌尿放射治疗小组(GFRU)制定

2025-09-040
PRE
Role of radiotherapy in the management of primary renal cell carcinoma: Recommendations from the Société franc,aise de radiothérapie oncologique (SFRO, the French society for radiation oncology)

放射治疗在原发性肾细胞癌管理中的角色:法国肿瘤放射治疗学会(SFRO,法国放射肿瘤学学会)的建议

2025-09-010
OAAI
Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial

短期雄激素剥夺疗法和高剂量放疗在中危和高危局限性前列腺癌中的应用:GETUG 14 随机III期试验结果

2025-08-140
OAAI
Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer

Pro益中患者报告的生活质量,一项3期随机临床试验,评估中度大分割放疗治疗中危前列腺癌

2025-05-060
PRE